drugset / Trial / NCT01243983

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

NCT01243983

Phase 3 Completed 155 enrolled Lux Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis).

Timeline

Start
2011-02
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 0.4 mg/kg Oral

Indications